Metriopharm AG has received a grant of €125,000 from charity Duchenne UK that will support development of the company's lead compound MP-1032 (luminol sodium salt) for the treatment of Duchenne muscular dystrophy (DMD).

Praetego Inc. has been awarded a US$2.5 million phase II Small Business Technology Transfer (STTR) award from the National Institute on Aging (NIA) to its advance lead candidate, PTG-630, for Alzheimer's disease.

Aqualung Therapeutics Corp. has been awarded two 3-year National Institutes of Health (NIH) Fast Track awards to support development of ALT-100 (enamptcumab), a humanized monoclonal antibody therapy for the chronic indications of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD).

Epivario Inc. has been awarded a grant of nearly $260,000 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to advance research on its proprietary small-molecule inhibitors designed to reduce alcohol craving responses and help people with alcohol use disorder (AUD) prevent relapse.

Evaxion Biotech A/S, in collaboration with UMass Chan Medical School, has received a grant from the U.S. National Institutes of Health (NIH) for the development of a lead vaccine candidate for gonorrhea.

I-Cordis LLC has been awarded a phase II Small Business Innovation Research (SBIR) grant for US$1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for heart failure with preserved ejection fraction (HFpEF).